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The mammalian skeleton is continuously remod-
eled. This process needs to be tightly regulated 
to maintain skeletal homeostasis while ensur-
ing structural integrity and support of metabolic 
functions. The number and activity of bone-
resorbing osteoclasts (OCs) and bone-forming 
osteoblasts (OBs) are balanced to ensure ho-
meostasis of the postdevelopmental skeleton. 
A complex network of endocrine and paracrine 
signals orchestrates bone remodeling by control-
ling mesenchymal and hematopoietic progeni-
tor cell differentiation and/or the activity of the 
mature cells. These signals converge to control 
the expression and activity of specific transcrip-
tion factors that modulate cellular functions by 
regulating the expression of their target genes 
(Karsenty et al., 2009). The activity of these tran-
scription factors is controlled by association with 
different activator or repressor complexes, some 
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Bone homeostasis is maintained by the coupled actions of hematopoietic bone-resorbing 
osteoclasts (OCs) and mesenchymal bone-forming osteoblasts (OBs). Here we identify early 
B cell factor 1 (Ebf1) and the transcriptional coregulator Zfp521 as components of the 
machinery that regulates bone homeostasis through coordinated effects in both lineages. 
Deletion of Zfp521 in OBs led to impaired bone formation and increased OB-dependent 
osteoclastogenesis (OC-genesis), and deletion in hematopoietic cells revealed a strong cell-
autonomous role for Zfp521 in OC progenitors. In adult mice, the effects of Zfp521 were 
largely caused by repression of Ebf1, and the bone phenotype of Zfp521+/ mice was 
rescued in Zfp521+/:Ebf1+/ mice. Zfp521 interacted with Ebf1 and repressed its tran-
scriptional activity. Accordingly, deletion of Zfp521 led to increased Ebf1 activity in OBs 
and OCs. In vivo, Ebf1 overexpression in OBs resulted in suppressed bone formation, similar 
to the phenotype seen after OB-targeted deletion of Zfp521. Conversely, Ebf1 deletion led 
to cell-autonomous defects in both OB-dependent and cell-intrinsic OC-genesis, a pheno-
type opposite to that of the Zfp521 knockout. Thus, we have identified the interplay 
between Zfp521 and Ebf1 as a novel rheostat for bone homeostasis.
© 2013 Kiviranta et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1. Zfp521 favors bone formation in mature OBs. (A) Generation of null and conditional Zfp521 alleles. Zfp521 genomic region encoding 
exon 4 is shown. Restriction fragment sizes are indicated as well as the positions of the internal and the two flanking probes used for genotyping analysis 
(Roman numerals). The shaded area indicates the part of the genomic region included in the targeting vector, and the three different alleles are shown. 
“neo” is the result of the gene-targeting event. “cko” is the conditional knockout allele derived from the neo allele after Flpe-mediated excision of the 
PGK-neo cassette. One Frt site and two loxP sites remain in the locus. “ko” is the null allele derived from the “neo” or from the “cko” allele by Cre-mediated 
recombination between the two loxP sites. Only a single loxP site remains in the modified locus. Splicing of exon 3 to exon 5 generates a frameshift.  
loxP and Frt sites are indicated as closed and open triangles, respectively. Neo, PGK-em7-neomycin dual selection cassette for bacteria and embryonic 
stem cells; TK, thymidine kinase cassette for counter-selection in embryonic stem cells; X, XbaI; B, BamHI; N, NotI. The genomic region is not drawn to scale. 
(B) Results of a Southern blot analysis of BamHI-digested tail DNA, probed with the internal probe (III). (C) Northern blot analysis of whole-brain RNA 
from 3-wk-old mice using a full-length Zfp521 cDNA probe. The blot was rehybridized with a Gapdh probe as a control for RNA quality. wt, wild type; 
exon4, position of the residual mRNA after removal of exon 4. (D) Genotyping PCR showing deletion of Zfp521 allele in genomic DNA extracted from 
Zfp521hOC/ long bones cleaned of soft tissues and BM. (E) Von Kossa staining of tibia sections in 3-wk-old global Zfp521/ mice and Zfp521+/+ littermate 
controls. (F) Histomorphometric analysis of samples in E (n = 5). (G) Trabecular BV (BV/tissue volume [TV]) at distal femoral metaphysis and in second lum-
bar vertebra in 3-wk-old Zfp521/ and control mice measured by CT (n = 5). (H) Von Kossa staining of tibia sections in 6-wk-old Zfp521hOC/ mice and 
littermate controls. (I) Histomorphometric analysis of samples in H (n = 6). (J) Trabecular BV (BV/TV) at distal femoral metaphysis and in second lumbar 
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in both OBs and OCs, such that the latter exerts a positive 
and coordinated influence on bone homeostasis. We have there-
fore identified the interaction between Zfp521 and Ebf1 as a 
novel regulator of bone homeostasis that functions in both 
mesenchymal and hematopoietic cells to modulate bone for-
mation and bone resorption in a coordinated manner, acting 
as a rheostat for bone homeostasis.
RESULTS
Germline deletion of Zfp521 decreases bone formation  
and increases bone resorption, leading to osteopenia
OB-targeted overexpression of Zfp521 leads to a high post-
developmental bone mass with a high bone formation rate (BFR; 
Wu et al., 2009). Here we sought to determine whether Zfp521 
was required for normal skeletal homeostasis by generating 
a germline deletion in mice (Fig. 1, A–D). The skeleton of 
Zfp521/ mice developed normally, but these mice were 
runted and survived only 4–5 wk. We therefore analyzed their 
bones at 3 wk of age. Histomorphometric analysis showed that 
Zfp521/ mice were osteopenic, with decreased mineral ap-
position rate (MAR; the activity of individual OBs) and BFR 
(BFR/bone volume [BV]; overall bone formation activity). 
Interestingly, this occurred despite increased OB numbers, 
suggesting that Zfp521 affects mostly OB function (Fig. 1, 
E and F; and Table S1). Low bone mass was confirmed by 
microcomputed tomography (CT) analysis, and lower P1NP 
levels in Zfp521/ mice verified the decrease in bone forma-
tion (Fig. 1, G and M). These mice also showed an increased 
number of OCs and eroded surfaces (ESs; ES/bone surface 
[BS]), as well as elevated levels of serum CTX (C-terminal 
telopeptide of type I collagen), showing that germline deletion 
of Zfp521 not only decreases bone formation but also increases 
bone resorption (Fig. 1, F and M).
Conditional deletion of Zfp521 in mature OBs decreases 
bone formation but does not affect bone resorption
To determine whether the effects of Zfp521 on bone homeo-
stasis were OB dependent, and to circumvent the early le-
thality of the full deletion, we generated conditional Zfp521 
knockouts targeted to mature OBs using the human osteocalcin 
(hOC)–Cre mouse line (Zhang et al., 2002). Unlike Zfp521/ 
mice, Zfp521hOC/ mice grew normally, allowing us to per-
form analysis in more mature skeletons, at 6 and 12 wk. Similar 
to the global knockout, histomorphometric analysis revealed 
that deletion of Zfp521 in OBs resulted in decreased BV (Fig. 1, 
H, I, K, and L; and Tables S2 and S3). The osteopenic pheno-
type was also confirmed by CT (Fig. 1 J). Bone formation was 
impaired, with both MAR and BFR/BV significantly decreased, 
although serum PINP (N-terminal propeptide of type I pro-
collagen) was not significantly decreased (Fig. 1, I, L, and N). 
of which are cell lineage specific, whereas others are relevant 
in multiple cell types but specifically regulated (MacDonald 
et al., 2009).
The regulation of bone homeostasis during remodeling 
involves three essential components: (1) OB differentiation and 
bone matrix production, (2) OB-dependent regulation of os-
teoclastogenesis (OC-genesis) through the secretion of recep-
tor activator of NF-B ligand (RANKL) and osteoprotegerin 
(OPG; Boyle et al., 2003), and (3) cell-autonomous regula-
tion of OC differentiation and bone resorption within hema-
topoietic OC precursors (Negishi-Koga and Takayanagi, 2009). 
Although much is known about the transcriptional program 
regulating OB and OC differentiation and function, our un-
derstanding of the coordinated regulation of these two lineages 
and bone remodeling as a whole is still only partial. For a single 
transcription factor to achieve such coordination, it would 
have to affect all the three components of bone remodeling 
to regulate bone formation and bone resorption in an opposite 
manner, i.e., increasing bone formation and reducing bone 
resorption to control bone mass. However, many transcription 
factors affect bone formation and resorption in parallel, not 
in an opposite manner. For instance, several AP1 transcription 
factors and Nfatc1 are positive regulators of OB function (Yang 
and Karsenty, 2004;  Yang et al., 2004; Koga et al., 2005; Bozec 
et al., 2010) but enhance OC-genesis either indirectly via OBs 
(ATF4) or in OC precursors (Nfatc1). Thus, these factors act 
more as rheostats for bone turnover, increasing both bone 
formation and resorption, rather than a rheostat for bone mass, 
a critical consideration in the clinic. FoxO family transcription 
factors, PPAR, and -catenin all function both in mesenchy-
mal and hematopoietic progenitors to regulate bone formation 
and resorption in an opposite manner, but even these key reg-
ulators do not affect all three components of bone remodeling 
(Glass et al., 2005; MacDonald et al., 2009; Wan, 2010; Almeida, 
2011; Kousteni, 2011; Wei et al., 2011; Otero et al., 2012).
The transcriptional regulators Zfp521 and early B cell fac-
tor 1 (Ebf1), both first identified in the hematopoietic system 
(Warming et al., 2003; Lukin et al., 2008), have recently emerged 
as important players in bone biology. Zfp521 interacts with 
and suppresses Runx2 activity to regulate early skeletal devel-
opment, whereas overexpression of Zfp521 in mature OBs pro-
motes bone formation (Wu et al., 2009; Hesse et al., 2010). 
Conversely, deletion of Ebf1 in mice results in increased bone 
formation and increased BM adiposity (Hesslein et al., 2009).
We show here that the interplay of Zfp521 and Ebf1 can 
coordinately regulate bone mass. Through its activity in both 
OBs and OCs, Zfp521 affects all three components of bone 
remodeling, positively affecting bone homeostasis. Furthermore, 
we show that the negative effects of Ebf1 on bone mass are 
endogenously repressed by the transcriptional modulator Zfp521 
vertebra in 12-wk-old Zfp521hOC/ and control mice measured by CT (n = 5–6). (K) Von Kossa staining of tibia sections in 12-wk-old Zfp521hOC/ mice 
and littermate controls. (L) Histomorphometric analysis of samples in K (n = 6). (M) Serum PINP and CTX levels in 3-wk-old global Zfp521/ mice and 
Zfp521+/+ littermate controls (n = 6–9). (N) Serum PINP and CTX levels in 6-wk-old Zfp521hOC/ and control mice (n = 5–6). N.Ob, number of OBs; N.Oc, 
number of OCs. All data are means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars: (E) 400 μm; (H and K) 600 μm. See also Tables S1–S3.
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Figure 2. Zfp521 is required for OB maturation. (A) Cryosections of 3-wk-old Zfp521/ and control mice showing the distal femoral metaphysis 
were immunostained for Runx2 (green). Nuclear DAPI staining (dark blue) and colocalization with Runx2 (light blue) are shown. Higher magnification 
images of the marked areas show trabecular surfaces. Asterisks indicate the growth plate, and arrows indicate the trabecular bone. Bar graph shows the 
ratio of Runx2+/total cell number quantified in the primary spongiosa from confocal images (n = 3 mice/genotype). (B) An equal number of BM cells 
flushed from Zfp521/ and control mice was plated on 6-well plates and cultured in osteogenic medium (OM) for 10 and 21 d. The cells were stained  
for ALP activity on day 10 to count the number of CFU-Fs and with Alizarin red for osteoblastic colonies (CFU-OB) on day 21. (C) Calvarial cells from 
Zfp521/, Zfp521hOC/, and respective control newborn mice were harvested and cultured on 6-well plates for 7 d in OM and stained for ALP activity. 
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unchanged but the expression of the mature OB marker genes 
Bone sialoprotein (Bsp) and Ocn was markedly decreased, further 
demonstrating impaired OB maturation in the absence of 
Zfp521 (Fig. 2, F and G). This finding was confirmed in vivo 
by in situ hybridization for Opn and Ocn (Fig. 2 H).
Thus, global and hOC-Cre–targeted Zfp521 deletions re-
sulted in similar impairment of OB maturation and function, 
but germline deletion increased bone resorption, whereas OB-
targeted deletion with the Ocn promoter did not. This discrep-
ancy suggested that the regulation of OCs by Zfp521 may 
occur in cells other than OBs and/or at earlier stages of dif-
ferentiation within the OB lineage, before efficient expression 
of Ocn. To address this question, we used two different but 
complementary approaches.
Zfp521 affects OB-dependent OC-genesis when deleted early
In vivo, we used osterix (Osx)-Cre mice to target Zfp521 
deletion to early OBs (Rodda and McMahon, 2006). Similar 
to Zfp521/ and Zfp521hOC/ mice, Zfp521Osx/ mice 
were osteopenic and exhibited impaired bone formation when 
compared with Cre-expressing Zfp521Osx+/+ control mice 
(Fig. 3 A and Table S4). However, like the Zfp521/ mice, 
Zfp521Osx/ mice exhibited increased number of OCs and 
ES, a change not observed in Zfp521hOC/. This result shows 
that Zfp521 controls OB-dependent OC-genesis in vivo in 
early cells within the OB lineage that express (or have ex-
pressed) Osx-Cre but in which the hOC promoter is not yet 
active (Fig. 3 B).
The main mechanism by which OBs regulate OC-genesis 
involves the secretion of RANKL and OPG. We therefore 
measured the production of these two cytokines in cells de-
rived from Zfp521/ mice. In vitro, OC production was strik-
ingly increased in Zfp521 total BM cultures when stimulated 
with parathyroid hormone (PTH), a known inducer of endog-
enous Rankl expression in OBs (Fig. 3 C). Comparison of classi-
cal co-cultures of calvarial cells from control or Zfp521/ mice 
mixed with nonadherent BM from wild-type or Zfp521/ 
animals showed that Zfp521/ calvarial cells were more 
efficient in supporting OC-genesis than control cells (Fig. 3 D), 
implicating Zfp521 in OB-dependent OC-genesis. In con-
trast, calvarial cells from control and Zfp521hOC/, in which 
OC numbers were not altered in vivo, did not differ in their 
capacity to support OC-genesis (not depicted). This con-
firmed that Zfp521 acts at a defined stage within the OB 
lineage to control OC-genesis. Zfp521/ calvarial cells 
expressed significantly more Rankl and less Opg mRNAs 
than control cells, resulting in a pronounced increase in the 
Interestingly, and again similar to the germline deletion, the 
number of OBs was increased in 6-wk-old Zfp521hOC/ 
mice, despite the decrease in BFR/BV (Fig. 1 I). This discrep-
ancy was maintained at 12 wk, with the BFR continuing to 
be low and the number of OBs remaining as high as in con-
trols (Fig. 1 L and Tables S2 and S3). Thus, the deletion of 
Zfp521 in mature OBs leads to a bone formation phenotype 
that is reversed compared with what we observed in mice over-
expressing Zfp521, also under the control of the osteocalcin 
(Ocn) promoter (Wu et al., 2009). These findings demonstrate 
that Zfp521 has a cell-autonomous, nonredundant function 
in mature OBs in vivo to promote bone formation. However, 
and in contrast with germline deletion, there was no differ-
ence in OC number, ES, or serum CTX in Zfp521hOC/ 
mice (Fig. 1, I, L, and N).
Zfp521 is required for OB maturation and function
The association of low MAR and BFR with an increase in 
OB numbers in Zfp521-deficient mice suggested that dele-
tion of Zfp521 induces the accumulation of poorly func-
tional OBs along trabecular surfaces and therefore that OB 
maturation could be altered in the absence of Zfp521. Con-
sistent with this hypothesis, we detected more OBs at early 
stages of differentiation along Zfp521/ trabeculae, using 
Runx2 as an osteoprogenitor marker (Fig. 2 A), and an in-
creased number of alkaline phosphatase (ALP)–positive fibro-
blast CFUs (CFU-Fs) in Zfp521/ BM (Fig. 2 B). Interestingly, 
the number of Alizarin red–positive colonies (CFU-OB) 
was only modestly increased, with only the number of small 
nodules being significantly increased, which suggests that 
the Zfp521/ progenitors are increased in numbers but are 
impaired in their OB function, i.e., their capacity to form 
large bone nodules.
In vitro, Zfp521/ calvarial cells exhibited decreased ALP 
staining (Fig. 2 C) and mRNA expression (not depicted) at 
day 7. As expected, there was no detectable change in ALP in 
Zfp521hOC/ cultures because hOC-Cre deleted Zfp521 in 
more mature cells after they became ALP positive (Fig. 2 C). 
The formation of mineralized bone nodules was compara-
bly impaired in both Zfp521/ and Zfp521hOC/ cultures 
(Fig. 2 D). In vitro, hOC-Cre deleted Zfp521 only in the frac-
tion of cells that became hOC-Cre positive, reducing the ap-
parent expression of Zfp521 in the total cell pool at day 14 
when Zfp521 expression is normally the highest (Fig. 2 E). 
The Zfp521/ and Zfp521hOC/ cultures shared nearly 
identical gene expression fingerprints, where the expression 
of early OB marker genes such as Osteopontin (Opn) was 
(D) Zfp521/, Zfp521hOC/, and control calvarial cells were cultured for 21 d in OM and stained with Alizarin red to detect mineralized bone nodules. 
Alizarin red–positive nodules were quantified (bar graphs). (E) Time course of Zfp521 and hOC-Cre expression in Zfp521hOC/ and control calvarial cells 
during OB differentiation was measured using quantitative RT-PCR (qRT-PCR) in RNA extracted from cultures in C and D. (F) Expression of late OB marker 
genes Bsp and Ocn was measured by qRT-PCR in Zfp521/ and control calvarial cells cultured for 21 d in OM. (G) Expression of late OB marker genes 
Bsp and Ocn was measured by qRT-PCR in Zfp521hOC/ and control calvarial cells cultured for 21 d in OM. (H) Expression of early (Opn) and late (Ocn) 
marker genes by in situ hybridization in Zfp521/ and control bones. All data are means ± SD. Similar results were obtained in at least three separate 
experiments performed in triplicate. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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However, these mix-and-match experiments also showed 
increased OC-genesis in Zfp521/ BM even when these cells 
were cultured with control calvarial cells, i.e., in the presence 
of a normal RANKL/OPG ratio. This suggests that Zfp521 
could also be involved in the regulation of OC-genesis through 
its activity within hematopoietic cells (Fig. 3 D).
Rankl/Opg ratio (Fig. 3 E), and the culture medium from 
Zfp521/ OBs contained significantly more Rankl pro-
tein than control medium (503.3 ± 38.6 pg/ml vs. unde-
tectable; Fig. 3 F). Thus, deletion of Zfp521 at early stages 
within the OB lineage increases the Rankl/Opg ratio, en-
hancing OC-genesis.
Figure 3. Zfp521 controls OB-dependent  
OC-genesis. (A) Von Kossa staining and histomor-
phometric analysis of tibia sections in 6-wk-old 
Zfp521Osx/ mice and littermate controls (n = 6–8). 
N.Ob, number of OBs; N.Oc, number of OCs; TV, tis-
sue volume. Bar, 520 μm. (B) Calvarial cells from 
Zfp521Osx/ and control newborn mice were har-
vested and cultured on 6-well plates in OM. RNA 
was extracted at the indicated times, and Zfp521 
and Osx-Cre expression were measured by qRT-PCR. 
(C) Total BM cells from Zfp521/ and control mice 
were plated on 48-well plates, stimulated with  
10 nM hPTH(1–34), and stained for TRAP. Number 
of TRAP+ multinucleated cells (MNCs) per well is 
shown. (D) Calvarial and nonadherent BM cells 
from control and Zfp521/ mice were mixed as indi-
cated in 24-well plates, stimulated with vitD3 and 
PGE2, and stained for TRAP. Bar graphs indicate the 
number of TRAP+ multinucleated cells per well. (E) RNA 
was extracted from the co-culture experiment in D, 
and the mRNA expression of Rankl and Opg and 
the Rankl/Opg ratio were quantified using  
qRT-PCR. (F) Control and Zfp521/ calvarial cells 
were cultured in 24-well plates and stimulated 
with vitD3 and PGE2 as in co-culture experiments. 
RANKL concentration in the controls was below 
detection limit (n = 3). All data are means ± SD. 
Similar cell number and mRNA data were obtained 
from at least three experiments with three to six 
replicates per condition. *, P < 0.05; **, P < 0.01; 
***, P < 0.001. See also Table S4.
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mechanisms contribute to the increased OC-genesis observed 
in vitro and in vivo when Zfp521 is absent within the hema-
topoietic lineage.
Thus, Zfp521 appears to regulate in a coordinated manner 
the three main aspects of bone homeostasis, i.e., bone forma-
tion, OB-dependent OC-genesis, and OC lineage–dependent 
OC-genesis, the net result being a net increase in bone mass. 
We then turned to identifying the mechanism by which Zfp521 
could mediate such a positive effect on the postdevelop-
mental skeleton.
Runx2 haploinsufficiency fails to rescue bone homeostasis 
in the Zfp521+/ postdevelopmental skeleton
We have previously shown that Zfp521 interacts with and re-
presses Runx2 activity such that haploinsufficiency of Zfp521 
rescues some aspects of the developmental bone phenotype of 
Runx2+/ mice (Hesse et al., 2010). We have also shown that 
this repressive activity of Zfp521 on Runx2 can prevent the 
negative influence of artificially increased Runx2 expression 
in OBs on adult skeleton (Hesse et al., 2010). Because in this 
model both proteins were artificially overexpressed, we sought 
to determine whether the interaction between Zfp521 and 
Runx2 was involved in the regulation of postdevelopmental 
bone homeostasis under more physiological conditions. For 
this purpose, we crossed Zfp521+/ with Runx2+/ mice and 
analyzed their bone density by CT at the postdevelop-
mental stage of 6 wk. As shown in Fig. 5 A, deletion of one 
allele of Runx2, which induced a mild osteopenia by itself, 
Zfp521 deletion in hematopoietic cells  
also increases OC-genesis
Confirming this hypothesis, RANKL-induced differentiation 
of BM and spleen-derived Zfp521/ OC progenitors was 
both more rapid and markedly increased (Fig. 4 A and not 
depicted, respectively). This was consistent across a range of 
RANKL concentrations (Fig. 4 A). To elucidate the mecha-
nisms by which Zfp521 could function within the OC lineage, 
we compared transcriptional profiling of known regulators of 
OC-genesis downstream of RANKL in control and Zfp521/ 
OC progenitors. The expression of Nfatc1 and of its target 
genes, Ctsk and Rank, was increased after RANKL stimulation 
in Zfp521/ OCs derived from BM macrophages (BMMs; 
Fig. 4 B). Moreover, Zfp521 repressed Nfatc1 transcriptional 
activity in an in vitro Cathepsin K promoter-luciferase assay in 
Raw-267 cells (Fig. 4 C). In addition, the expression of Ccl9, an 
Ebf1 target gene which has been reported to enhance RANKL-
stimulated OC-genesis (Okamatsu et al., 2004), was up-
regulated at steady-state (not depicted) and was markedly 
increased 4 h after RANKL stimulation in Zfp521/ cultures 
(Fig. 4 D). Blocking Ccl9 activity by neutralizing anti-Ccl9 
antibody normalized OC-genesis in Zfp521/ OC progenitor 
cells (Fig. 4 E). These data suggest that Zfp521 controls OC-
genesis by two complementary mechanisms. First, Zfp521 reg-
ulates the autocrine expression of Ccl9 in OC progenitors, 
enhancing RANKL-stimulated OC-genesis. Second, Zfp521 
controls the activity of RANK downstream signaling by in-
hibiting Nfatc1 transcriptional activity. Together, these two 
Figure 4. Zfp521 acts in OC progenitor 
cells to control OC-genesis. (A) Control and 
Zfp521/ spleen cells were stimulated with 
20 ng/ml M-CSF and then with increasing 
doses of RANKL for 3 d, stained for TRAP ac-
tivity, and quantified. Bar, 64 μm. (B) BMM-
derived OCs were cultured with 20 ng/ml 
M-CSF and then M-CSF + 100 ng/ml RANKL 
for the indicated times, and expression of 
Nfatc1, Ctsk, and Rank was measured by 
qRT-PCR. (C) Ctsk-Luciferase reporter con-
struct was transfected to RAW264.7 cells 
together with Zfp521, constitutively active 
NFATc1, or both. Luciferase activity was 
normalized to cotransfected Renilla activity. 
(D) Nonadherent BM cells were cultured for  
2 d with 20 ng/ml M-CSF and then stimulated 
for 4 h with 100 ng/ml RANKL and 20 ng/ml 
M-CSF, and expression of Ccl9 was measured 
by qRT-PCR. (E) Control and Zfp521/ spleen 
cells were cultured with 20 ng/ml M-CSF and 
50 ng/ml RANKL for 5 d in the presence of 
blocking anti-Ccl9 antibody, IgG, or vehicle. 
Cells were fixed and stained for TRAP activ-
ity and quantified. All data are means ± SD. 
Similar cell number and mRNA data were 
obtained from three independent experi-
ments with three to six replicates per condi-
tion. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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dysregulation of Ebf1 transcriptional activity, we crossed 
Zfp521+/ mice with Ebf1+/ heterozygous mice. Unlike 
haploinsufficiency of Runx2, deletion of one allele of Ebf1 
was able to rescue the osteopenic phenotype of Zfp521+/ 
mice (Fig. 5, C and D). Furthermore, full histomorphometric 
analysis (Fig. 5, C and D; and Table S5) of these mice at 6 wk 
of age showed that both bone formation and bone resorp-
tion parameters were altered, and in an opposite manner: BFR 
was decreased and OC numbers (N.Oc/BS) and activity 
(ES/BS) were increased in Zfp521+/ mice, whereas the op-
posite was true in Ebf1+/ mice. Each and all of these param-
eters were normalized in the compound heterozygote mutants, 
strongly suggesting that the dysregulation of Ebf1 transcrip-
tional activity was a critical contributor to the postdevelop-
mental alterations of bone homeostasis after deletion of Zfp521, 
affecting both bone formation and bone resorption.
Ebf1 target genes are markedly up-regulated  
in OBs in the absence of Zfp521
These findings suggested that deletion of Zfp521 enhanced 
Ebf1 activity. As reported, we found that both endogenous 
and overexpressed Zfp521 and Ebf1 coimmunoprecipitate 
(Fig. 6, A and B) and Zfp521 suppresses Ebf1 transcriptional 
activity (Fig. 6 C). Consequently, and in contrast with Runx2 
target genes, we found a strong and consistent increase in 
the expression of several Ebf target genes (Ccl9, Cxcl12, 
and PPAR; Jimenez et al., 2007; Lagergren et al., 2007) in 
Zfp521/ and in Zfp521hOC/ cells, showing that Ebf tran-
scriptional activity is indeed markedly increased in the ab-
sence of Zfp521 (Fig. 6 D).
failed to restore the osteopenic phenotype induced by Zfp521 
haploinsufficiency, demonstrating that increased Runx2 activity 
is not influencing the Zfp521 postdevelopmental phenotype. 
Furthermore, we measured several Runx2 target genes in un-
differentiated Zfp521-deficient calvarial cells (day 0) and in fully 
differentiated OBs (day 21) but found no significant changes in 
the expression of any of the Runx2 target genes examined (Osx, 
Opn, Bsp, and Ocn) at early stages (Fig. 5 B). In contrast Bsp and 
Ocn were not only unaltered but even markedly down-regulated 
in fully differentiated OBs (Fig. 2 F). This data suggested that, al-
though Zfp521 regulation of Runx2 plays a critical role at early 
developmental stages, this interaction does not contribute to the 
physiological regulation of postdevelopmental bone homeo-
stasis. Because OB-targeted overexpression of Zfp521 increases 
bone formation and bone mass (Wu et al., 2009) and OB- 
targeted Zfp521 deletion leads to osteopenia, we then asked 
which transcription factor other than Runx2 could be both reg-
ulated by Zfp521 and important for adult bone homeostasis.
Ebf1 haploinsufficiency rescues bone homeostasis  
in the postdevelopmental Zfp521+/ skeleton
Several lines of evidence called our attention to the transcrip-
tion factor Ebf1 as a possible candidate. First, Zfp521 has been 
previously shown to interact with and repress Ebf1 in B cells 
in vitro (Mega et al., 2011). Second, deletion of Ebf1 has been 
reported to increase bone formation and bone mass in vivo 
(Hesslein et al., 2009), and third, Ccl9, which we found mark-
edly increased in BM cells in the absence of Zfp521, is a well-
known target gene of Ebf1.
To test the hypothesis that some of the effects we ob-
served in bone in the absence of Zfp521 could be related to 
Figure 5. Ebf1 haploinsufficiency rescues the 
bone phenotype of Zfp521+/ mice. (A) CT 
analysis of tibias from control, Zfp521+/, 
Runx2+/, and Zfp521+/:Runx2+/ mice at 6 wk 
(n = 4–6). (B) mRNA expression of Runx2 target 
genes in Zfp521/ and control calvarial cells at 
day 0 of the culture. (C) Von Kossa staining of 
tibia sections of 6-wk-old control, Zfp521+/, 
Ebf1+/, and Zfp521+/:Ebf1+/ mice. Bar, 450 μm. 
(D) Histomorphometric analysis of samples in C 
(n = 6). All data are means ± SD. Similar mRNA 
data were obtained from three independent 
experiments with three replicates per condition. 
N.Oc, number of OCs; TV, tissue volume. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.
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zinc fingers (Zfp521C) reduced the binding of Zfp521 to 
Ebf1 (not depicted; Mega et al., 2011). On B cell–specific B29 
promoter, the Zfp521N mutant was significantly less efficient 
in repressing Ebf1, although Ebf1 did not lose all of its tran-
scriptional activity (Fig. 6 G). Deletion of the last four zinc fin-
gers also resulted in partial loss of suppression of Ebf1 activity 
Zfp521 contains a nucleosome remodeling and deacety-
lase (NuRD) complex–binding domain at its N terminus 
(Fig. 6 E; Matsubara et al., 2009), and deletion of the first 
13 aa (Zfp521N) abolished its interaction with several NuRD 
components (Fig. 6 F). In contrast, Ebf1 interacts with the 
last four zinc fingers of Zfp521 (ZFs1-26), and deletion of these 
Figure 6. Zfp521 antagonizes Ebf1 activity. (A) Ebf1 was immunoprecipitated with -Ebf1 antibody. Mouse IgG was used as control. The immune 
complexes (left) and 10% input were blotted with -Ebf1 and -Zfp521 as indicated. (B) HA-Zfp521 and Flag-Ebf1 proteins were overexpressed in 293T 
cells. Proteins were immunoprecipitated with -HA, and the immune complexes (two top panels) and 5% of the original cell lysates (two bottom panels) 
were blotted with -HA and -Flag as indicated. (C) Ebf1-responsive B29-luc plasmid was transfected into 293T cells together with Ebf1, Zfp521, or both. 
Luciferase activity was normalized to cotransfected Renilla activity. (D) The expression of Ebf1 target genes Cxcl12, Ccl9, and Ppar was measured by 
qRT-PCR in Zfp521/, Zfp521hOC/, and respective control calvarial cells cultured for 7 d in OM. (E) Schematic presentation of Zfp521 domain structure 
and mutants. (F) HA-Zfp521 and HA-Zfp521N were overexpressed in 293T cells and immunoprecipitated with anti-HA antibody. The Western blot was 
performed with antibodies against endogenous NuRD complex proteins (MTA1, MTA2, and HDAC2) and anti-HA antibody. (G) B29-luc plasmid was trans-
fected into 293T cells together with Ebf1 and Zfp521 or Zfp521-deletion mutants as indicated. Luciferase activity was normalized to cotransfected Renilla 
activity. (H) B29-luc plasmid was transfected into 293T cells together with Ebf1 and Zfp521 or Zfp521C as indicated. Luciferase activity was normalized 
to cotransfected Renilla activity. (I) Ccl9-luc plasmid was transfected into 293T cells together with Ebf1 and Zfp521 or Zfp521-deletion mutants as indi-
cated. Luciferase activity was normalized to cotransfected Renilla activity. All data are means ± SD. Similar results were obtained in at least three inde-
pendent experiments, and the assays were performed in triplicate. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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activity on several other Ebf1 target promoters (Mega et al., 
2011; Kang et al., 2012). Thus, it appears that the mecha-
nisms by which Zfp521 interacts with and/or represses Ebf1 ac-
tivity are promoter and possibly cellular context dependent.
OB-targeted overexpression of Ebf1 mimics the effects  
of conditional deletion of Zfp521 on bone formation
To further establish that increased Ebf1 activity contributed 
to the phenotype of Zfp521-deficient mice, we targeted over-
expression of Ebf1 in mature OBs, hypothesizing that this could 
result in a bone phenotype similar to that of Zfp521hOC/ 
mice. To test this, we generated transgenic mice that over-
express Ebf1 in OBs using the rat collagen I 2.3-kb pro-
moter (Woitge et al., 2001; Wu et al., 2009), leading to a 
(Fig. 6 H). Consequently, a double mutant that lacked both 
the N-terminal NuRD and C-terminal Ebf1-binding sites 
(Zfp521CN; Fig. 6 E) had a markedly reduced ability to 
repress Ebf1 (Fig. 6 G). More relevant to bone, Ebf1 efficiently 
activated the Ccl9-Luc reporter, which was suppressed by 
Zfp521 (Fig. 6 I). In contrast to the B29 promoter, Zfp521C 
retained full suppressive capability, suggesting the presence of 
another binding site or an indirect interaction with Ebf1. 
Most importantly, the Zfp521N and Zfp521CN mutants 
lost all ability to repress Ebf1 activity on the Ccl9 promoter 
(Fig. 6 I). Based on our data, Zfp521-dependent recruitment 
of the NuRD complex to Ebf1 contributes significantly to 
the suppression of Ebf1 activity on the Ccl9 promoter, whereas 
it is only partially or not required for the repression of Ebf1 
Figure 7. Ebf1 suppresses bone formation  
in vivo and in vitro. (A) Ebf1 expression in bone 
RNA from control and ColI2.3-Ebf1 transgenic 
mice measured by qRT-PCR (n = 6). (B) Von Kossa 
staining and histomorphometric analysis of tibia 
sections in 6-wk-old ColI2.3-Ebf1 transgenic 
and control mice (n = 6). N.Ob, number of OBs. 
Bar, 600 μm. (C) Metaphyseal trabecular BV 
(BV/tissue volume [TV]) in distal femurs of  
6-wk-old ColI2.3-Ebf1 mice measured by CT 
(n = 6). (D) ColI2.3-Ebf1 and control calvarial 
cells were harvested from newborn mice, plated 
on 6-well plates, and cultured in OM for 21 d. 
Expression of Ebf1 target genes was measured 
by qRT-PCR. (E) ALP (blue) and Alizarin red (red) 
staining of ColI2.3-Ebf1 and control calvarial cells 
cultured in OM for 7 d or 21 d, respectively. Bar 
graph shows quantification of bone nodules in 
the Alizarin red–stained plates. (F) Expression 
of OB marker genes Opn, Bsp, and Ocn in 
ColI2.3-Ebf1 and control calvarial cells after  
21 d in OM was measured by qRT-PCR.  
(G) Col1a1 expression in Zfp521/, Zfp521hOC/, 
and ColI2.3-Ebf1 and respective control calvarial 
cells after 21 d in OM was measured by qRT-PCR. 
(H) Ebf1-containing chromatin complexes were 
immunoprecipitated from control and Flag-Ebf1–
overexpressing MC3T3-E1 cells using anti-Flag 
antibody. IgG was used as negative control.  
The region of the ColI2.3kb promoter containing 
the putative Ebf1-binding site was amplified by 
PCR. (I) ColI2.3kb-luc reporter was transfected 
into C3H10T1/2 cells together with Ebf1, Zfp521, 
or both. Luciferase activity was normalized to 
cotransfected Renilla activity. All data are mean ± 
SD. Similar mRNA and reporter assay data were 
obtained from at least three experiments per-
formed in triplicate. *, P < 0.05; **, P < 0.01.
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twofold overexpression of Ebf1 in long bones (Fig. 7 A). The 
bone phenotype of the ColI-Ebf1 mice was a phenocopy of 
Zfp521hOC/ mice, with low BV and low MAR and miner-
alizing surface/BS leading to decreased BFR (Fig. 7, B and C; 
and Table S6). The ColI-Ebf1 phenotype was also the op-
posite of the Ebf1/ mice (Hesslein et al., 2009), thereby 
confirming the negative role of Ebf1 on bone formation and 
that it is cell autonomous to OBs. As with Zfp521 deletion, the 
decrease in BFR occurred despite increased OB numbers, 
indicating that the function of individual OBs was impaired. 
Importantly, overexpression of Ebf1 targeted to mature OBs 
led to increased expression of the same Ebf1 target genes as in 
Zfp521-deleted OBs (Ccl9, Cxcl12, and PPAR; Figs. 7 D 
and 6 D). Both Zfp521hOC/ and ColI-Ebf1 calvarial cells 
formed less mineralized bone nodules in vitro, whereas early 
OB differentiation and ALP activity were not affected (Fig. 7 E). 
Accordingly, ColI-Ebf1 cells expressed lower levels of mature 
OB markers (Bsp and Ocn), indicating impaired maturation 
and function (Fig. 7 F).
Interestingly, gene expression profiling of calvarial cells 
isolated from Zfp521-deleted and Ebf1-overexpressing mice 
revealed that in all cases, expression of the Col1a1 gene was 
decreased (Fig. 7 G). In silico analysis of the Col1a1 promoter 
identified a putative Ebf1-binding site, and a chromatin im-
munoprecipitation (ChIP) assay showed that Ebf1 did in fact 
occupy this promoter region (Fig. 7 H). Furthermore, although 
Zfp521 had no effect by itself, Ebf1 suppressed the activity of 
ColI 2.3-kb promoter-luciferase construct, and this suppres-
sion was relieved by coexpressing Zfp521 (Fig. 7 I). These data 
show that increased Ebf1 activity inhibits bone formation 
in vivo and in vitro, at least partly by directly suppressing type I 
collagen expression, a negative effect which is reversed by 
Zfp521. Thus, OB-targeted overexpression of Ebf1 recapitu-
lated all the hallmarks of the phenotype of Zfp521hOC/ mice 
in vivo and in vitro, suggesting that the mechanism by which 
Zfp521 deletion impairs OB maturation and bone formation 
involves the up-regulation of Ebf1 transcriptional activity.
Ebf1 regulates OB-dependent and hematopoietic  
lineage–dependent OC-genesis
To test whether Ebf1 also regulates OB-dependent OC-genesis, 
we performed BM cultures and mix-and-match experiments, 
now using Ebf1/ cells. Stimulation of total BM from Ebf1/ 
mice with PTH resulted in significantly decreased OC-genesis 
compared with controls (Fig. 8 A). Similarly, Ebf1/ calvarial 
cells exhibited impaired support of OC-genesis from wild-type 
BM, demonstrating a role for Ebf1 in the regulation of OB-
dependent OC-genesis (Fig. 8 B). Deletion of Ebf1 resulted 
in a threefold decrease in Rankl/Opg ratio, opposite to the 
Zfp521/ phenotype (Fig. 8 C). In agreement with the mRNA 
data, Rankl protein levels were significantly decreased in the 
Ebf1/ cultures (Fig. 8 D).
As Zfp521 and Ebf1 had divergent effects on the expres-
sion of Rankl, we analyzed the effects of the two proteins on 
the regulation of this promoter. A search of the proximal pro-
moter and distal enhancer regions revealed an Ebf1 consensus 
sequence in the distal enhancer region, previously shown to be 
required for PTH-induced activation (Fig. 8 E; Fu et al., 2002, 
2006; Kitazawa and Kitazawa, 2002). ChIP analysis showed 
that both Zfp521 and Ebf1 could bind the distal enhancer but 
not the proximal promoter (Fig. 8 E and not depicted). Endog-
enous Zfp521 occupied the distal enhancer at steady-state but 
was rapidly displaced by treatment of the cells with PTH, which 
led to a robust (30-fold) increase in Rankl expression (Fig. 8 F). 
With time, Zfp521 returned to the enhancer region, followed 
by a decrease in Rankl expression. Collectively, our data dem-
onstrates that Zfp521 and Ebf1 regulate Rankl expression in an 
opposite manner in cells of the OB lineage by binding to its 
distal enhancer region.
Zfp521 and Ebf1 were both expressed in OC progenitors, 
and their expression decreased identically upon induction of 
differentiation with RANKL (Fig. 8, G and H). We therefore 
tested whether the interaction between Zfp521 and Ebf1 also 
had cell-autonomous effects in OC progenitors. In contrast 
with the accelerated OC-genesis of BM and spleen-derived 
Zfp521/ OC progenitors, spleen cells and BMMs derived 
from Ebf1/ mice required longer time and higher concen-
tration of RANKL to form OCs, confirmed by decreased ex-
pression of OC marker genes in a time course experiment 
(Fig. 8, I and J; and not depicted, respectively). These in vitro 
findings were therefore consistent with histomorphometric 
analysis of bone resorption in both Zfp521+/ and Ebf1+/ 
mice (Fig. 5 D). Thus, in addition to their role within OBs in 
regulating bone formation and the RANKL/OPG ratio, the 
interplay of these molecules in OC precursors is also an im-
portant cell-autonomous determinant of OC differentiation, 
most likely through regulation of Ccl9 expression, an Ebf1 
target gene reported to enhance RANKL-stimulated OC-
genesis (Okamatsu et al., 2004).
DISCUSSION
Bone mass is under complex regulation by endocrine and para-
crine signals, which modulate bone formation via OB differ-
entiation and function, and bone resorption through both 
OB-dependent and hematopoietic lineage–autonomous mech-
anisms. We found that alterations in the balance between 
Ebf1 and the 30–zinc finger transcriptional coregulator Zfp521 
affects in a coordinated manner the regulation of all three as-
pects of bone homeostasis, i.e., bone formation and both OB-
dependent and OC precursor–intrinsic OC-genesis. Thus, the 
interaction between Ebf1 and Zfp521 in both the mesenchy-
mal and the hematopoietic lineages acts as a rheostat for bone 
homeostasis that coordinates the activities of OBs and OCs to 
regulate bone mass.
Zfp521 represses Ebf1 to maintain bone homeostasis
Zfp521 interacts with Ebf1 and suppresses its transcriptional ac-
tivity, such that deletion of Zfp521 enhanced Ebf1 target gene 
expression in cells of both the OB and the OC lineages. In OBs, 
high Ebf1 activity results in impaired bone formation. Targeted 
overexpression of Ebf1 in mature OBs in vivo recapitulated 
the low bone formation phenotype of Zfp521hOC/ mice. 
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Figure 8. Ebf1 and Zfp521 regulate OB-dependent and hematopoietic lineage–dependent OC-genesis. (A) Total BM cells from Ebf1/ and con-
trol mice were plated on 48-well plates, stimulated with 10 nM hPTH(1–34), and stained for TRAP. Number of TRAP+ multinucleated cells (MNCs) per well is 
shown. (B) Calvarial cells from control and Ebf1/ mice were co-cultured with nonadherent BM cells as indicated in 24-well plates, stimulated with vitD3 
and PGE2, and stained for TRAP. Bar graphs indicate the number of TRAP+ multinucleated cells per well. (C) Rankl and Opg mRNA expression and Rankl/Opg 
ratio measured by qRT-PCR in the co-culture experiment in B. (D) RANKL protein levels were measured with RANKL ELISA in medium samples from control 
and Ebf1/ calvarial cells cultured in 12-well plates and stimulated with vitD3 and PGE2 as in co-culture experiments (n = 3). (E) ChIP with anti-V5 antibody 
for V5-Zfp521 and anti-Flag antibody for Flag-Ebf1 in MC3T3-E1 cells overexpressing the tagged proteins. IgG was used as control. The PCR-amplified  
promoter area contained a putative Ebf1 consensus site in the active distal promoter region. (F) The time courses of PTH-induced Rankl mRNA expression 
and displacement and rebinding of endogenous Zfp521 from the Rankl distal promoter region after stimulation by 10 nM PTH were compared. Zfp521 
binding to the promoter was analyzed in a ChIP assay using the anti-Zfp521 antibody. IgG was used as control. (G) Expression of Zfp521 mRNA by qRT-PCR 
in OC progenitors cultured with 20 ng/ml M-CSF for 2 d and then stimulated with 100 ng/ml RANKL for the indicated times. (H) Expression of Ebf1 mRNA 
by qRT-PCR in OC progenitors cultured as in G. (I) Control and Ebf1/ spleen cells were stimulated with 20 ng/ml M-CSF and then with increasing doses of 
RANKL for 5 d, stained for TRAP activity, and quantified. Bar, 100 μm. (J) Expression of Nfatc1, Ctsk, and Rank mRNAs by qRT-PCR in Ebf1/ spleen cell–
derived OCs cultured with 20 ng/ml M-CSF and then M-CSF + 100 ng/ml RANKL for the indicated times. All data are mean ± SD. Similar cell number and 
mRNA data were obtained from three independent experiments with four to six replicates per condition. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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deletion of Zfp521 in early OBs (Osx-Cre) affects OC-genesis, 
deletion of Zfp521 (hOC-Cre) or targeted overexpression of 
Ebf1 (ColI2.3-Ebf1) in more mature cells does not. We can-
not however exclude the possibility that some of these regu-
latory events could also take place in matrix-embedded cells.
Most importantly, our study shows for the first time that 
besides their opposing function in OBs, Ebf1 and Zfp521 also 
act cell-autonomously within the monocyte-macrophage lin-
eage to regulate OC-genesis. Zfp521 acts within OC progeni-
tors to inhibit their differentiation, whereas Ebf1 is required 
for normal differentiation. These data are consistent with the 
hypothesis that increased Zfp521 expression is involved in 
the maintenance of undifferentiated hematopoietic cell phe-
notypes (Warming et al., 2003; Bond et al., 2004; Hentges 
et al., 2005). Again confirming the opposition between Zfp521 
and Ebf1, but now in hematopoietic cells, OC numbers were 
decreased after deletion of one Ebf1 allele, increased after de-
letion of one allele of Zfp521, and normalized in the double 
heterozygous mutants. Notably, the osteoclastogenic potential 
of Ebf1/ progenitors in vitro was also clearly decreased, es-
tablishing firmly that Ebf1 promotes OC-genesis within he-
matopoietic cells.
What is the mechanism by which the interaction between 
Zfp521 and Ebf1 regulates OC-genesis? Besides the oppos-
ing roles of Zfp521 and Ebf1 in the regulation of the Rankl 
promoter in OBs, the Ebf1–Zfp521 interaction also affected 
OCs directly. We show that the up-regulation of OC-genesis 
in Zfp521/ mice occurred by at least two separate but syn-
ergistic mechanisms. First, deletion of Zfp521 resulted in in-
creased expression of the Ebf1 target gene Ccl9 (Lagergren 
et al., 2007). Ccl9 and its receptor Ccr1 have been reported 
to be the main chemokine ligand receptor pair expressed in 
OCs, enhancing RANKL-induced OC-genesis (Lean et al., 
2002; Okamatsu et al., 2004). Consistent with Ccl9 playing a 
critical role in our model, blocking Ccl9 with a neutralizing 
antibody was sufficient to normalize OC-genesis in Zfp521/ 
cultures. However, in this experiment, Zfp521/ OCs still 
showed enhanced OC-genesis compared with controls, sug-
gesting that an additional mechanism was involved. Indeed, 
we found that Zfp521 inhibits Nfatc1 transcriptional activity 
in OCs such that the expression of several known Nfatc1 tar-
get genes was increased after Zfp521 deletion. Thus, Zfp521 
represses OC-genesis not only by altering the RANKL/OPG 
ratio in cells of the OB lineage but also by suppressing RANK 
signaling at several levels. It inhibits an Ebf1-dependent Ccl9 
autocrine loop in OC precursors, decreasing their sensitivity 
to RANKL, and suppresses Nfatc1 activity, a critical down-
stream signaling effector of RANK.
Zfp521 as a transcriptional modulator
What is the molecular mechanism by which Zfp521 represses 
Ebf1? Zfp521 is a component of transcriptional complexes, 
but it lacks any classical transactivation domains. Instead it con-
tains clusters of C2H2 Krüppel-like zinc fingers, suggesting 
that it could act as a platform to assemble transcriptional com-
plexes. Indeed, Zfp521 interacts with its N terminus with 
Further demonstrating this relationship, the impaired bone 
formation and low bone mass of Zfp521+/ mice was rescued 
in Zfp521+/:Ebf1+/ double heterozygous mice. Importantly, 
although Zfp521 can repress Runx2 and some of the early 
skeletal defects in Runx+/ mice are rescued in Zfp521+/:
Runx2+/ pups (Wu et al., 2009; Hesse et al., 2010), Runx2 
haploinsufficiency did not rescue the Zfp521+/ low bone 
mass phenotype. The lack of rescue of osteopenic phenotype 
in Zfp521+/:Runx2+/ may be at least in part caused by the 
low endogenous Runx2 levels in mature OBs and in the post-
developmental skeleton (Maruyama et al., 2007). Thus, in ad-
dition to its interaction with Runx2 to regulate early OB lineage 
differentiation at developmental stages (Wu et al., 2009; Hesse 
et al., 2010), Zfp521 also interacts with and controls the ac-
tivity of Ebf1 to regulate OB maturation and bone formation, 
the latter being predominant in the mature skeleton.
Derepression of Runx2 activity may nevertheless also con-
tribute to the phenotype observed after deletion of Zfp521. 
We have previously shown that supraphysiological levels of 
Zfp521 suppress early OB differentiation in vitro but also 
promote bone formation in vivo (Wu et al., 2009). Our find-
ings may now help explain this apparent contradiction. Dele-
tion of Zfp521 increased the number of Runx2-positive cells 
as well as the number of CFU-Fs and CFU-OBs, confirming 
that Zfp521 tends to repress early OB differentiation, and this 
most likely through repression of Runx2. Yet these accumu-
lating early OBs exhibit impaired capacity to progress to full 
maturity and to form bone in the absence of Zfp521, suggesting 
that Runx2-positive cells cannot differentiate further without 
Zfp521. Our results suggest that this late stage effect on OBs 
is caused by derepression of Ebf1. We therefore propose that 
in the regulation of the OB lineage, Runx2 is predominant at 
early stages and Ebf1 at later stages. By repressing both, Zfp521 
would decrease early differentiation but favor late maturation 
of OBs and bone formation. As a matter of fact, Zfp521 expres-
sion kinetics with increased expression at later stages during 
OB differentiation would indeed favor the latter, consistent 
with its recently proposed positive role during neuronal dif-
ferentiation (Wu et al., 2009; Kamiya et al., 2011).
Zfp521 and Ebf1 regulate bone resorption  
in both hematopoietic and mesenchymal cells
Bone resorption is a critical component of bone remodeling 
and of the regulation of bone homeostasis. Deletion of Zfp521 
led to an increase in OC numbers and serum CTX as the 
result of effects in both OBs and OCs. In OBs, Ebf1 stimu-
lated the expression of Rankl and Zfp521 had opposite effects. 
ChIP analysis showed that both Ebf1 and Zfp521 associate di-
rectly with the Rankl promoter to reciprocally regulate its 
transcription. In contrast, Ebf2 has been reported to regulate 
OC-genesis through OPG and not RANKL expression in OBs 
(Kieslinger et al., 2005). Recent studies have suggested that 
the osteocytes may be the major source of RANKL in adult 
bone, whereas OBs and hypertrophic chondrocytes would be 
an important source only during growth (Nakashima et al., 
2011; Xiong et al., 2011). Interestingly, we found that although 
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components of bone remodeling to regulate bone homeostasis. 
Thus, the interplay of these two factors acts as a rheostat to 
regulate bone homeostasis.
MATERIALS AND METHODS
Generation of conditional knockout construct for Zfp521. The DNA 
construct for simultaneous generation of a null and a conditional allele for 
Zfp521 was made using recombineering, essentially as described previously 
(Liu et al., 2003; Warming et al., 2006). First, a retrieval vector was prepared 
by three-way ligation of mini-homology arms into pBlight-TK (a plasmid 
backbone containing the thymidine kinase from HSV) for counter-selection 
in embryonic stem cells using Ganciclovir (Warming et al., 2006). The 
homology arms were amplified from a mouse BAC containing the Zfp521 
genomic region using the primers listed below. The BAC (CITB 454L20) 
was identified by screening a 129-based BAC library (CJ7 embryonic stem 
cell DNA, CITB, Research Genetics/Invitrogen), and BAC DNA was pre-
pared using the BAC Nucleobond kit (Takara Bio Inc., BD). All primers 
were from Integrated DNA Technologies, and all PCR reactions were 
performed using Expand High Fidelity (Roche): 5 retrieval F, 5-AATA-
AAGGATCCGTGCTCCAGGCACTATAGAT-3; 5 retrieval R, 5-AAT-
AAAAAGCTTGACCTGGCCAGGTCATTTAA-3; 3 retrieval F, 5-AAT-
AAAAAGCTTGCCTTTCCAAGTTCCTGACA-3; and 3 retrieval R, 
5-AATAAAGCGGCCGCGTTCAAGGCCACTGTGGTTT-3. Cloning 
sites were BamHI, HindIII, and NotI.
The Zfp521 BAC was transferred into DY380 cells. Next, heat-shocked 
and electrocompetent DY380/Zfp521 cells were electroporated with HindIII-
linearized retrieval vector to subclone 13.7 kb of genomic Zfp521 DNA, 
to give rise to pZfp521. For further manipulation of pZfp521, two mini-
targeting vectors for recombineering in Escherichia coli were prepared essen-
tially as described previously (Liu et al., 2003). The following primers were 
used to amplify mini-homology arms, using Zfp521 BAC DNA as template: 
5 F1, 5-AAATAAGTCGACCTTTTGGTCTGCAGAATTGCCT-3; 
5 R1, 5-AAATAAGAATTCGAGCCCCAAGCTTTTACTCTT-3; 
5 F2, 5-AAATAAAGATCTAGAGCGATGCTCACTCCTTCC-3; 5 R2, 
5-AAATAAGCGGCCGCCGGCTAAAGGACTTGTCACA-3; 3 F1, 
5-AAATAAGTCGACGCACAACAGGAGTTTTTCAAAGC-3; 3 R1, 
5-AAATAAGAATTCGGATCCCAAGGGACAAGGTTTTCCCT-3; 
3 F2, 5-AAATAAAGATCTCAGGTGTGGTTCCTGTAAGT-3; and 
3 R2, 5-AAATAAGCGGCCGCCAGGAACCACTATCCAAGCT-3.
5 F1 + 5 R1 PCR product was digested with SalI + EcoRI, 5 F2 + 5 
R2 was digested with BglII + NotI, 3 F1 + 3 R1 with SalI and EcoRI, and 3 
F2 + 3 R2 with BglII + NotI. An EcoRI–BamHI loxP-PGK-em7-Neo-loxP 
fragment was isolated from PL452, and an EcoRI–BamHI Frt-PGK-em7-
Neo-Frt-loxP fragment was isolated from PL451 (Liu et al., 2003). A SalI–NotI 
pBluescript backbone fragment was prepared from PL452 as well.
A 5MTV (5 mini-targeting vector) was made by a four-way ligation 
of the two 5 PCR products, the EcoRI–BamHI loxP-Neo-loxP fragment 
from PL452, and the SalI–NotI backbone. Likewise, a 3MTV was made by 
a four-way ligation of the two 3 PCR products, the EcoRI–BamHI Frt-
PGK-em7-Neo-Frt-loxP fragment, and the SalI–NotI backbone.
Next, using recombineering, a floxed neo cassette was inserted upstream 
of Zfp521 exon 4: A NotI + SalI digested fragment from the 5MTV contain-
ing the floxed neo cassette flanked by mini-homology arms was co-electro-
porated with pZfp521 into heat-shocked and electrocompetent DY380 cells 
to give rise to pZfp521-5neo. Then, pZfp521-5neo was electroporated into 
Cre-induced EL350 cells to remove the neo cassette and leave behind a single 
loxP site, to give rise to pZfp521-5loxP. Finally, a NotI + SalI–digested frag-
ment from 3MTV, containing the frted neo cassette with a single loxP site 
flanked by mini-homology arms, was co-electroporated with pZfp521-5loxP 
into heat-shocked and electrocompetent DY380 cells to give rise to pZfp521-
CKO. This targeting vector contains the genomic Zfp521 region with one 
loxP site and an engineered XbaI site for genotyping upstream of exon 4 and 
a loxP-frt-neo-frt cassette along with an engineered BamHI site for genotyp-
ing downstream of exon 4. The pZfp521-CKO targeting vector was linearized 
using NotI and electroporated into CJ7 embryonic stem cells (129 background) 
components of the NuRD complex and binds to Ebf1 via its 
C-terminal zinc fingers, but whether NuRD was required for 
transcriptional repression by Zfp521 remained unresolved. We 
and others have previously found that the Zfp521–NuRD in-
teraction is dispensable for the repression of Runx2 (Correa 
et al., 2010; Hesse et al., 2010) or of some Ebf1-responsive pro-
moters (Mega et al., 2011; Kang et al., 2012). However, the 
NuRD-binding domain is required for the efficient repres-
sion of GATA-1 activity by Zfp521 during erythroid differ-
entiation (Matsubara et al., 2009). Thus, Zfp521 might exert 
its repressive action on transcription through several mecha-
nisms, one of which requires the recruitment of NuRD.
Indeed, we show here that on a B cell–specific B29 pro-
moter, deletion of the N-terminal NuRD-binding domain 
partially impaired the ability of Zfp521N to repress Ebf1, 
which was further reduced in the Zfp521NC mutant, al-
though it still retained some repressive function. In contrast, 
on the Ccl9 promoter, the NuRD interaction was required 
for efficient repression of Ebf1, whereas the C-terminal Ebf1-
binding domain was dispensable. These results confirm that 
several mechanisms are involved in the repressive function of 
Zfp521 on gene transcription and suggest that (a) the require-
ment of NuRD interaction for Zfp521 to repress target genes 
of the same transcription factor, here Ebf1, or of different tran-
scription factors, such as Runx2 or GATA1, may be promoter 
specific and (b) direct interaction of Zfp521 to Ebf1 (or to other 
target factor) may not be required for efficient repression. The 
latter could be mediated by an intermediate, such as the NuRD 
complex itself. More studies will be required to unravel the 
molecular mechanisms by which Zfp521 represses transcrip-
tion in these different contexts.
The specific function of Zfp521 could go as far as reversing 
its role from a repressor to an activator of transcription, as sug-
gested by Kamiya et al. (2011) in the regulation of neuronal 
differentiation or by Hentges et al. (2005) in murine lympho-
mas. Based on their data in lymphoma cells, Hentges et al. (2005) 
actually propose that on B cell–related Ebf1 target genes, Zfp521 
could even enhance Ebf1 activity, whereas on other promoters 
Zfp521 would be a repressor. Whether this activation would 
be direct or indirect through Zfp521 binding to and inhibiting 
repressors remains to be explored. Supporting this latter hy-
pothesis, we found here that Zfp521 enhances Col1a1 expres-
sion, a key target gene for bone formation in mature OBs, but 
this occurs through the relief of the Ebf1-mediated suppression 
of Col1a1. Collectively, these data suggest that Zfp521 regu-
lates the transcriptional program in different cell types through 
interactions with a specific subset of transcription factors, re-
cruiting specific transcriptional complexes to modulate cell dif-
ferentiation and function.
In summary, by repressing Ebf1, Zfp521 exerts a cell-
autonomous positive influence on OB maturation and bone 
formation and a negative influence on OB-dependent and on 
OC precursor cell–autonomous regulation of OC-genesis and 
bone resorption. Collectively, our results demonstrate that one 
single transcription factor, Ebf1, and its regulation by one sin-
gle repressor, Zfp521, affect in a coordinated manner three key 
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described (Okamatsu et al., 2004). For co-cultures, calvarial cells were 
plated at 104/well on 24-well plates. The next day, 1–2 × 106 nonadherent 
BM cells were plated into the same wells in medium containing 108 M 
vitamin D3 and 106 M prostaglandin E2. ALP and tartrate-resistant acid 
phosphatase (TRAP) staining and RNA extraction were performed at in-
dicated time points as previously described (Takahashi et al., 1988; Sabatakos 
et al., 2000). Soluble RANKL was measured in the pooled medium samples 
with Quantikine Mouse RANKL assay (R&D Systems) after concentrating 
the samples with Microcon YM-10 columns (EMD Millipore). C3H10T1/2 
and MC3T3-E1 cells were infected with either Flag-tagged Ebf1 retrovirus 
or V5-tagged Zfp521 lentivirus or corresponding empty viruses and selected 
with puromycin or blasticidin, respectively. Cells were cultured in -MEM sup-
plemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Reporter assays and coimmunoprecipitation. For reporter assays, 293T 
or C3H10T1/2 cells were transfected with appropriate plasmids including pRL 
promoterless Renilla plasmid using Fugene 6 reagent (Invitrogen). Reporter 
activity was measured with the Dual Luciferase Reporter assay (Promega) 
24–48 h after transfection and normalized for Renilla activity. Coimmuno-
precipitations were performed as described previously (Wu et al., 2009). The 
CMV-LacZ plasmid was included in each transfection condition, and all 
coimmunoprecipitations were normalized according to the -galactosidase 
activity in the cell lysate.
Plasmids. CMV-HA-Zfp521 was previously described (Wu et al., 2009). 
pCDNA3-Flag-Ebf1 and pMSCV-Flag-Ebf1 constructs (Jimenez et al., 2007) 
were a gift from E.D. Rosen. B29-Luc and Ccl9-Luc were gifts from 
M. Sigvardsson (Linköping University, Linköping, Sweden; Lagergren et al., 2007; 
Sigvardsson, 2000). ColI2.3kb-Luc and Ctsk-Luc were gifts from H. Takayanagi 
(Tokyo Medical and Dental University, Tokyo, Japan; Koga et al., 2005). 
HAHA-Zfp521N was generated by using PCR primers removing the 
first 13 5 codons and cloning this truncated Zfp521 cDNA in frame to 
CMV-HAHA vector according to standard methods. HA-Zfp521C and 
HAHA-Zfp521NC were generated from CMV-HA-Zfp521 and from 
HAHA-Zfp521N by replacing the methionine 1181 by a premature stop 
codon (in bold) using Multi Site-directed Mutagenesis kit (Agilent Technolo-
gies) with primer 5-ACGCCCCAAGTGTCACCCTAGCCCAGAATCA-
GTCCCTCCCAGTCCG-3.
Antibodies. The in-house–generated Zfp521 antibody -Zfp521(369) 
was previously described (Wu et al., 2009). -Zfp521, monoclonal anti-
HA clone 12CA5 (Roche), and anti-Flag clone M2 (Sigma-Aldrich) 
were used for immunoprecipitation and Western blotting as indicated. 
Goat anti–mouse and anti–rabbit HRP were used as a secondary antibod-
ies, and HRP activity was detected with Amersham ECL Detection re-
agents (GE Healthcare).
ChIP. ChIP was performed using the Chromatin Immunoprecipitation 
Assay kit (EMD Millipore) according to the manufacturer’s protocol with 
slight modifications. In brief, calvarial cells or MC3T3-E1 cells were fixed 
in 1% formaldehyde for 15 min at room temperature. The cross-linking was 
stopped with 0.1 M glycine. After chromatin shearing, antibodies were added 
to samples and incubated overnight. Magnetic Dynabeads Protein A beads 
(Invitrogen) were used to harvest bound protein–chromatin complexes. 
Extracted chromatin was subjected to PCR using promoter-specific primer 
sequences: RANKL promoter CNS1A-F, 5-GGTCAAGAGGGGCCT-
GACTT-3; and CNS1A-R, 5-GCAGTGTGTAAACAAAGAGA-3; and 
Col1a1 promoter Col1a1-F3, 5-TGGCTCCCCCTCTCCGAG-3; and 
Col1a1-R3, 5-TCTAGACCCTAGACATGTAG-3.
Measurement of gene expression. Total RNA was isolated using RNeasy 
mini kit (QIAGEN), cDNA was prepared with SuperScript VILO kit (Invitro-
gen), and quantitative real-time PCR was performed using iQ SYBR Green 
Supermix (Bio-Rad Laboratories). The data were normalized using GAPDH as 
internal control. Primer sequences are provided per request.
using standard methods. G418 and FIAU double-resistant embryonic stem cell 
clones were selected and analyzed using Southern blot hybridization on XbaI 
(5)- and BamHI (3)-digested genomic DNA. 7/47 clones were targeted 
(15%), and one of them had the single 5 loxP site (1/47 = 2%). The correctly 
targeted embryonic stem cell clone was injected into C57BL/6 blastocysts ac-
cording to standard methods to give rise to chimaeras.
Production of mice. After germline transmission of the targeted neo allele, 
heterozygous neo mice were crossed to -actin Flp mice to remove the neo cas-
sette and produce mice carrying the fl/+ allele. Heterozygous fl/+ mice were 
then either intercrossed to produce homozygous fl/fl mice or crossed to -actin 
Cre mice to produce heterozygous Zfp521+/ mice. Heterozygous Zfp521+/ 
mice were then intercrossed to produce homozygous Zfp521/ mice.
Experimental animals. Osx-Cre and hOC-Cre transgenic mice have been 
previously described (Zhang et al., 2002; Rodda and McMahon, 2006). 
Experimental mice were produced by heterozygous matings. Zfp521+/ mice 
were maintained on C57BL background (over 10 backcrosses). Homozygous 
deletion of Zfp521 on C57BL/6 background was lethal during the first 24 h. 
To generate Zfp521/ animals, we backcrossed Zfp521+/ mice once to 
129/Sv, and then these F1 heterozygous mice on mixed background were in-
tercrossed to produce control and Zfp521/ animals. These animals survived 
until weaning and some up to 4–5 wk of age. Runx2+/ mice have been pre-
viously described (Otto et al., 1997) and were maintained on pure C57BL 
background (over 10 backcrosses). Zfp521+/:Runx2+/ mice were produced 
by heterozygous matings, and wild-type littermates were used as controls.
Wild-type littermates were used as controls for Zfp521/ mice. 
Either Osx-Cre+; Zfp521+/+ or hOC-Cre+; Zfp521+/+ littermates served as 
controls in experiments examining the effects of the conditional deletions, 
and these animals were maintained on mixed 129/Sv-C57BL background. 
ColI2.3-Ebf1 transgenic mice were generated by pronuclear injection of a 
construct containing the 2.3-kb fragment of the rat Col1a1 promoter 
(Woitge et al., 2001) linked to mouse Ebf1 cDNA. Mice were generated 
and maintained on pure C57BL background and genotyped by transgene-
specific primers. Ebf1+/ mice were provided by J. Hagman (National 
Jewish Health, Denver, CO) and R. Grosschedl (Max Planck Institute of 
Immunobiology and Epigenetics, Freiburg, Germany; Lin and Grosschedl, 
1995), maintained on C57BL background, and crossed with Zfp521+/ mice 
to produce the experimental animals. Primer sequences for genotyping are 
provided per request. All procedures involving animals were approved by 
the Harvard Medical Area Standing Committee on Animals and conform 
to the relevant regulatory standards.
Histology, histomorphometry, CT, serum markers, in situ hybrid-
ization, and immunohistochemistry. Bone histomorphometry was per-
formed on secondary spongiosa 400 µm under the growth plate as previously 
described (Sabatakos et al., 2000). Five to eight animals were analyzed per 
group. CT was performed with Scanco CT-35 for femurs and with Skyscan 
1072 for vertebrae. 3D structural analysis was performed with software pro-
vided by the supplier. Serum samples were analyzed for PINP and CTX using 
Rat/Mouse PINP and RatLaps EIA assays (IDS) at Pharmatest Ltd. In situ 
hybridization was performed on decalcified, paraffin-embedded sections using 
[35S]UTP-labeled riboprobes for Opn and Ocn as described previously (Lanske 
et al., 1998). Three samples were analyzed per genotype. Immunohistochem-
istry was performed on frozen sections of decalcified tibias from 3-wk-old 
Zfp521/ and control mice as previously described (Wu et al., 2009).
Cell culture, cell lines, and medium RANKL. Calvarial cells were pre-
pared and induced to differentiate to OBs as described previously (Sabatakos 
et al., 2000). OC progenitors were harvested either from the nonadherent 
fraction of flushed BM or from spleen. The cells were first cultured in 20 ng/ml 
M-CSF (R&D Systems) for 2 d and then stimulated with 20 ng/ml M-CSF 
and 100 ng/ml RANKL unless otherwise stated for the indicated times. To 
block Ccl9 activity, anti-Ccl9 blocking antibody (R&D Systems) or 5 µg/ml 
IgG control was added to the OC culture medium (20 ng/ml M-CSF and 
50 ng/ml of RANKL) from the beginning of the culture as previously 
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